PSB INDUSTRIES (HEALTHCARE & INDUSTRY) acquired by CLAYENS GROUP
Context
This operation represents the first programmatic bolt-on acquisition executed by Clayens NP since its primary sponsor-backed buyout, designed to accelerate the platform’s diversification into highly resilient and high-margin healthcare manufacturing verticals. Negotiated on a proprietary bilateral basis due to long-standing industrial relationships and a previous site acquisition in 2017, the transaction allows the seller, PSB Industries, to complete its strategic pivot toward luxury and beauty packaging while divesting a non-core industrial asset. The acquisition adds >€50 million in revenue to Clayens NP, driving consolidated group sales toward €350 million and establishing an essential manufacturing bridgehead in Mexico to serve the North American nearshoring market. The transaction funding mechanism leverages a combination of available balance sheet cash and a structured share swap, resulting in PSB Industries taking a minor equity position within the Clayens holding structure alongside the existing sponsor pool and management. This structural alignment facilitates management continuity, ensures operational stability across the five acquired sites, and underpins the strategic cross-selling of polymer and cleanroom manufacturing capabilities to the combined global customer base.
PSB INDUSTRIES (HEALTHCARE & INDUSTRY), which reported an EBITDA margin of in 2020, is valued in this transaction at an EV/EBITDA multiple of , a level to compare with the average currently observed in the Industry & Manufacturing sector (11.6x).
-> Deep-dive in Industry & Manufacturing market trends
Target
The healthcare and industry division of PSB Industries operates as a highly specialized technical contract manufacturer of advanced polymer components and precision plastic assemblies across five manufacturing facilities located in France, Poland, and Mexico. The operational infrastructure is defined by the utilization of five certified ISO7 cleanroom environments, which are technically mandatory to comply with the rigid sanitary, regulatory, and validation standards governing the medical, pharmaceutical, and diagnostic end-markets. Revenue generation within this business unit is derived from long-term supply arrangements linked to customer-owned proprietary tooling and injection molds, creating deep commercial integration and high customer switching costs that protect the asset from volume volatility.
Ent. Value
Equity Value
Multiples
EV / Revenue
EV / EBITDA
EV / EBIT
Historical Financials (EUR)
Similar deals in Chemicals & Materials
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 11/2020 | CRODA INTERNATIONAL | IBERCHEM GROUP | SPAIN | Flavors & Fragrances |
| 10/2020 | ARDIAN | ADVANCION (ANGUS CHEMICAL) | UNITED STATES | Specialty Chemicals |
| 07/2020 | PARTNERS GROUP | Rovensa | PORTUGAL | Specialty Chemicals |
| 06/2020 | CEREA PARTNERS / BPIFRANCE | AXIUM PACKAGING | FRANCE | Plastic Packaging |
| 03/2020 | ALLIANCE ETIQUETTES | 5 SEPT ETIQUETTE | FRANCE | Labels & Adhesives |
| 03/2020 | SPARRING CAPITAL | PURE TRADE WORLDWIDE | FRANCE | Packaging & Containers |
| 02/2020 | SOFIMAC REGIONS / ESFIN PARTICIPATIONS | PONCIN METAL | FRANCE | Metallurgy / Foundry |
| 01/2020 | COBEPA | GERFLOR | FRANCE | Flooring |
| 01/2020 | KAMAN CORPORATION | BAL SEAL ENGINEERING | UNITED STATES | Plastics |
| 12/2019 | GREEN ARROW CAPITAL | POPLAST | ITALY | Plastic Packaging |
REFERENCES
Revenue range: 50M - 100M EUR
Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of PSB INDUSTRIES (HEALTHCARE & INDUSTRY) by CLAYENS GROUP are reserved for mynth community members. Register for free to unlock full data.
Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.
Press release: view release
Acquirer: clayens group